EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY 4.0

The Safety, Tolerability, and Pharmacokinetics of Active Ingredients From Hydroxysafflor Yellow A in Healthy Chinese Volunteers

Xiuli Zhao, Shanye Gu, Xia Wang, Yefeng Cai, Ziyi Zhou

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1487 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Xiuli Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Institution of Drug Clinical Trial Used for People, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Chalcone, Healthy Volunteers, Quinones. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Discipline Research Priority Project Plan of Guangzhou University of Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hydroxysafflor yellow A (HSYA), an active ingredient extracted from Carthami flos , shows potential for treating ischemic stroke. This phase 1 study assessed the safety, tolerability, and pharmacokinetic (PK) properties of HSYA in healthy Chinese volunteers who received intravenous infusions of pure HSYA powder. The study comprised 2 parts. Part A was a randomized, double‐blind, placebo‐controlled dose‐escalation study that evaluated safety and tolerability. This included a single‐dose study with 7 dose levels of HSYA (6.25, 12.5, 25, 50, 75, 100, and 125 mg) in 52 volunteers, and a multidose study (100 and 125 mg) in 16 volunteers. Part B was an open‐label study where 12 volunteers received 75 mg of HSYA once daily for 14 consecutive days to examine PKs. There were no adverse events (AEs) leading to treatment discontinuation by HSYA throughout the treatment period. All reported AEs were mild and did not require special treatment. PK analysis revealed rapid absorption (median T max of 1.1 hours) and elimination (median t 1/2 4.0 and 4.7 hours) of HSYA. Total body clearance on the 1st and 14th days was 1.7 and 1.6 L/h, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChalconeHealthy VolunteersQuinonesAdultFemaleHumansMaleYoung AdultArea Under CurveChinaDose-Response Relationship, DrugDouble-Blind MethodEast Asian PeopleHalf-LifeInfusions, Intravenous

Stichwörter der Autor:innen

PKshydroxysafflor yellow Aischemic strokesafetytolerability

Substanzen

Chalconehydroxysafflor yellow AQuinones

Autor:innen und Institutionen

  • The Institution of Drug Clinical Trial Used for People, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
  • The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Youcare Pharmaceutical Group Co., Ltd, Beijing, China.

Förderung

  • Discipline Research Priority Project Plan of Guangzhou University of Chinese Medicine

Zitieren

APA

Zhao, X., Gu, S., Wang, X., Cai, Y., & Zhou, Z. (2025). The Safety, Tolerability, and Pharmacokinetics of Active Ingredients From Hydroxysafflor Yellow A in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1487

Vancouver

Zhao X, Gu S, Wang X, Cai Y, Zhou Z. The Safety, Tolerability, and Pharmacokinetics of Active Ingredients From Hydroxysafflor Yellow A in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1487

BibTeX
@article{Zhao2025,
  author = {Zhao, Xiuli and Gu, Shanye and Wang, Xia and Cai, Yefeng and Zhou, Ziyi},
  title = {The Safety, Tolerability, and Pharmacokinetics of Active Ingredients From Hydroxysafflor Yellow A in Healthy Chinese Volunteers},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1487}
}
Kostenlos starten →